Jojo Gifty M, Kuppusamy Gowthamarajan, Selvaraj Kousalya, Baruah Uday Krishna
Department of Pharmaceutics, JSS College of pharmacy, Ootacamund, JSS Academy of Higher Education & Research, Mysore, India.
J Diabetes Metab Disord. 2019 May 9;18(1):229-242. doi: 10.1007/s40200-019-00405-2. eCollection 2019 Jun.
Late onset Alzheimer's disease (AD) is the most common cause of dementia among elderly. The exact cause of the disease is until now unknown and there is no complete cure for the disease. Growing evidence suggest that AD is a metabolic disorder associated with impairment in brain insulin signalling. These findings enriched the scope for the repurposing of diabetic drugs in AD management. Even though many of these drugs are moving in a positive direction in the ongoing clinical studies, the extent of the success has seen to influence by several properties of these drugs since they were originally designed to manage the peripheral insulin resistance. In depth understandings of these properties is hence highly significant to optimise the use of diabetic drugs in the clinical management of AD; which is the primary aim of the present review article.
晚发性阿尔茨海默病（AD）是老年人痴呆最常见的病因。该病的确切病因至今不明，且尚无完全治愈方法。越来越多的证据表明，AD是一种与脑胰岛素信号传导受损相关的代谢紊乱疾病。这些发现拓宽了在AD治疗中重新利用糖尿病药物的范围。尽管其中许多药物在当前的临床研究中进展良好，但由于它们最初是设计用于治疗外周胰岛素抵抗的，其成功程度似乎受到这些药物多种特性的影响。因此，深入了解这些特性对于优化糖尿病药物在AD临床治疗中的应用非常重要；这是本综述文章的主要目的。
